DNMT3A and myelodysplastic syndrome: DNA methyltransferase inhibitors (e.g., decitabine, azacitidine/5-azacytidine) are in clinical testing for adults with AML and MDS, and a recent trial demonstrated improved response rates in adults with DNMT3A-mutant AML who were treated with decitabine (110).